Hero Banner
Agenda
Wednesday, October 18
Pre-Conference: The Role of Digital Health & Technology in Cardiometabolic Risk Reduction: Where We Are and Where Are We Going
11:30 AM — 11:35 AM
Opening Remarks
Chair: Seth Martin, MD, MHS
11:35 AM — 11:55 AM
Setting the Stage: What Digital Health Means for Clinicians and Patients
Patrick Dunn, PhD
Technology & Digital Health in Lifestyle and Obesity
11:55 AM – 12:15 PM
Health and Care Apps for Lifestyle and Obesity: The Importance of Self-Monitoring
Tiffany Powell-Wiley, MD, MPH
12:15 PM – 12:35 PM
Continuous Glucose Monitoring: The New Frontier in Lifestyle Management?
Athena Philis-Tsimikas, MD
12:35 PM – 12:55 PM
Changing Behavior Using Digital Health for Long Term Weight Management
Martin S. Hagger, PhD
12:55 PM – 1:05 PM
Panel Discussion and Audience Q&A
Moderator: Seth Martin, MD, MHS
Panelists: Tiffany Powell-Wiley, MD, MPH; Athena Philis-Tsimikas, MD; Martin S. Hagger, PhD
Technology & Digital Health in Type 2 Diabetes
1:05 PM – 1:20 PM
Refresh and Recharge Break
1:20 PM – 1:50 PM
The Role of CGM in the Management of Type 2 Diabetes: Patient Selection & Important Pearls
Supported by Dexcom.
Grazia Aleppo, MD, FACE, FACP
1:50 PM – 2:10 PM
Insulin Delivery and Insulin Pumps in Patients with Type 2 Diabetes
Viral S. Shah, MD
2:10 PM – 2:20 PM
Panel Discussion and Audience Q&A
Moderator: Seth Martin, MD, MHS
Panelists: Grazia Aleppo, MD, FACE, FACP; Viral Shah, MD
Technology & Digital Health in CVD & CVD Risk Reduction
2:20 PM – 2:40 PM
Technology to Close Gaps in Hypertension Care
Daichi Shimbo, MD
2:40 PM – 3:00 PM
Advances in Digital Health for Arrhythmia Management
Mohamed B. Elshazly, MD, MBEE, FACC
3:00 PM – 3:20 PM
Health Technologies for CVD Prevention
Francoise Marvel, MD
3:20 PM – 3:30 PM
Panel Discussion and Audience Q&A
Moderator: Seth Martin, MD, MHS
Panelists: Daichi Shimbo, MD; Mohamed B. Elshazly, MD, MBEE, FACC: Francoise Marvel, MD
Technology & Digital Health in Cardiometabolic Health: Discussions & Practical Strategies for Implementation
3:30 PM – 3:45 PM
Refresh and Recharge Break
3:45 PM – 4:15 PM
Discussions & Perspectives: What Role Does Technology and Digital Health Play in Addressing Disparities in Care?
Moderator: Seth Martin, MD, MHS
Panelists: Yvonne Commodore-Mensah, PhD, MHS, RN; Christie M. Ballantyne, MD
4:15 PM – 4:45 PM
How Do Clinicians and Patients Better Use This Data: Challenges and Possible Solutions
Moderator: Seth Martin, MD, MHS
Panelists: Francoise Marvel, MD; Eric D. Peterson, MD, MPH
4:45 PM – 5:15 PM
Fireside Chat Reception
Light bites and drinks will be served.
5:15 PM – 6:30 PM
Fireside Chat (Non-CME)
Insights from Industry – Next Frontiers in Digital Interventions to Improve Cardiometabolic Health
Moderator: Seth Martin, MD, MHS
Panelists: Patrick Dunn, PhD; Grant Groves, PhD; Stephen Lynch; Francoise Marvel, MD; Kapil Parakh, MD, MPH, PhD
6:30 PM – 7:00 PM
Fireside Connect
Mix and mingle with industry experts and colleagues following the Fireside Chat.
Thursday, October 19
FDA Updates and Keynote
7:00 AM – 7:45 AM
PME Breakfast Symposium (non-CME)
A Treatment Option for Patients with Heart Failure
Sponsored by AstraZeneca.
Surendra Sivarajah, MD; Justin Fongemie, PharmD
7:45 AM – 8:15 AM
Refresh and Recharge Break
8:15 AM – 10:15 AM
Opening Remarks & FDA Update and Late Breaking Trials
Moderator: Christie M. Ballantyne, MD
Presenters: Deepak L. Bhatt, MD; Robert H. Eckel, MD; Keith C. Ferdinand; Anne L. Peters, MD
10:15 AM – 10:45 AM
Keynote Address
Screening for Social Determinants of Cardiometabolic Health & Practice Implications
A. Enrique Caballero, MD
10:45 AM – 11:15 AM
Exhibit Hall Break
11:15 AM – 12:15 PM
PME Lunch Symposium (non-CME)
Explore This GLP-1 RA For Your Patients With T2D and Established
Sponsored by Novo Nordisk
Matthew Budoff, MD, FACC, FAHA
Session I: Obesity & Lifestyle
12:15 PM – 12:45 PM
Exhibit Hall Break
12:45 PM – 12:45 PM
Opening Remarks
Robert H. Eckel, MD
12:45 PM– 1:45 PM
Diving Deeper Into Exercise Regimens for Cardiometabolic Health
Mercedes Carnethon, PhD; Jane Reusch, MD
1:45 PM– 2:45 PM
Debate and Discussion: Is it Time to Compare High-Intensity Pharmacotherapy to Surgery for the Management of Obesity?
Donna H. Ryan, MD; Christopher D. Still, DO
2:45 PM – 3:15 PM
Exhibit Hall Break
3:15 PM – 3:35 PM
The Intersection of Sleep and Cardiometabolic Risk: Important Connections and Practice Implications
Sirimon Reutrakul, MD
3:35 PM – 4:35 PM
Primetime CME Symposium
The Intersection of NASH and Cardiometabolic Risk: Applying Advances in Diagnosis and Management To Tackle The NASH Epidemic
Supported by an educational grant from Novo Nordisk.
Chair: Robert H. Eckel, MD
Faculty: Diana Barb, MD; Amreen Dinani, MD, MSc
4:35 PM – 5:30 PM
Challenging Obesity Cases & Panel Discussion
Moderator: Robert H. Eckel, MD
Panelists: Mercedes Carnethon, PhD; Jane Reusch, MD; Donna H. Ryan, MD; Sirimon Reutrakul, MD; Christopher D. Still, DO
5:30 PM – 6:30 PM
Welcome Reception
6:30 PM – 7:30 PM
Dinner Symposium (Non-CME)
Discover EVKEEZA
Sponsored by Regeneron Pharmaceuticals
Matthew Budoff, MD, FACC, FAHA followed by an EVKEEZA patient
Friday, October 20
7:00 AM – 8:00 AM
CME Breakfast Symposium
Understanding the Role of Lp(a) as a CV Risk Marker to Therapeutic Target in the Prevention of ASCVD
Supported by an educational grant from Novartis Pharmaceuticals Corporation.
Chair: Patrick M. Moriarty, MD
Faculty: Christie M. Ballantyne, MD; Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC
Session II: Dyslipidemia/Atherosclerosis/Thrombosis
8:00 AM – 8:05 AM
Opening Remarks
Christie M. Ballantyne, MD
8:05 AM – 8:25 AM
Colchicine for Chronic Atherosclerosis as an Adjunct to Statin Therapy
Paul Ridker, MD
8:25 AM – 8:45 AM
Statin Intolerance: How To Assess and Practical Pearls for Addressing It
Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC
8:45 AM – 9:05 AM
Hypertriglyceridemia: Trials, Tribulations, and Transition to Clinical Practice
Michael D. Shapiro, DO
9:05 AM – 10:25 AM
Primetime CME Symposium
Exploring Novel Strategies for LDL-C Combination Therapy to Decrease ASCVD Risk: A Paradigm Shift
Supported by an educational grant from Novartis Pharmaceuticals Corporation.
Chair: Christie M. Ballantyne, MD
Faculty: Pamela B. Morris, MD; Pam R. Taub, MD, FACC, FASPC
10:25 AM – 11:25 AM
Challenging Lipid Management Cases & Panel Discussion
Moderator: Christie M. Ballantyne, MD
Panelists: Robert H. Eckel, MD, Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC; Patrick M. Moriarty, MD, FACP, FACC, FNLA, FESC; Pamela B. Morris, MD; Paul Ridker, MD; Michael D. Shapiro, DO
11:25 AM – 11:55 AM
Exhibit Hall Break
11:55 AM – 12:55 PM
PME Lunch Symposium (non-CME)
Identifying and Discussing the Unmet Needs in the Management of Severe Hypertriglyceridemia
Sponsored by Ionis Pharmaceuticals, Inc.
Michael D. Shapiro, MD
12:55 PM – 1:25 PM
Exhibit Hall Break
Session III: Diabetes
1:25 PM – 1:25 PM
Opening Remarks
Anne L. Peters, MD
1:25 PM – 1:45 PM
Where Are We With Respect to Glycemic Control in T2D? A 2023 Update
Vanita R. Aroda, MD
1:45 PM – 2:10 PM
Early Treatment Intensification in Type 2 Diabetes
Juan P. Frias, MD
2:10 PM – 3:10 PM
Heterogeneity of Diabetes & Panel Discussion
Anne L. Peters, MD
3:10 PM – 3:40 PM
Exhibit Hall Break
3:40 PM – 4:00 PM
Optimizing Glycemic Control With Commonly-Available Combination Therapies: Tips and Pearls
Athena Philis-Tsimikas, MD
4:00 PM – 4:20 PM
How Social Determinants of Health Impact Type 2 Diabetes Treatment
Shivani Agarwal, MD, MPH
4:20 PM – 5:20 PM
Challenging Diabetes Management Cases & Panel Discussion
Moderator: Anne L. Peters, MD
Panelists: Shivani Agarwal, MD, MPH; Vanita R. Aroda, MD; Juan P. Frias, MD; Athena Philis-Tsimikas, MD
5:20 PM – 6:30 PM
Happy Hour & Giveaways
Saturday, October 21
Session IV: CardioRenal
7:00 AM – 8:00 AM
PME Breakfast Symposium (non-CME)
Cycloset Reduced CVD Outcomes Within 1 year in T2D Subjects: Identified Contributory Mechanisms – Published Study Results
Sponsored by VeroScience.
Anthony H. Cincotta, PhD
8:00 AM – 8:30 AM
Refresh and Recharge Break
8:30 AM – 8:30 AM
Opening Remarks
Keith C. Ferdinand, MD
8:30 AM – 9:35 AM
Tackling the Disproportionate Burden of Resistant Hypertension in Black Adults: Perspectives & Advances
• Overcoming Barriers to Hypertension Control and Cardiovascular Disease: We Need to Do Better
• Resistant Hypertension: Definitions, Current Treatment and Emerging Approaches
Supported by an independent medical educational grant from Medtronic.
Keith C. Ferdinand, MD; Debbie Cohen, MD
9:35 AM – 10:05 AM
Sleep and Hypertension: A Two-Way Street
Virend K. Somers, MD, PhD
10:05 AM – 10:35 AM
The Role of Steroidal and Non-steroidal MRAs in Cardiorenal Risk Reduction
Ajay K. Singh, MBBS, FRCP, MBA
10:35 AM – 10:50 AM
Refresh and Recharge Break
10:50 AM – 11:10 AM
Which Patients Should Get SGLT2is and GLP-1 RAs for cardiorenal risk reduction? Interpreting Guidelines and Clinical Trials to Patient Care
Pam R. Taub, MD, FACC, FASPC
11:10 AM – 11:30 PM
The Continuum of Heart Failure
Alanna A. Morris MD, MSc, FHFSA, FACC, FAHA
11:30 PM – 12:30 PM
Challenging Cardiorenal Cases & Expert Panel Discussion
Moderator: Keith C. Ferdinand, MD
Panelists: Debbie Cohen, MD; Alanna Morris MD, MSc, FHFSA, FACC, FAHA; Ajay K. Singh, MBBS, FRCP, MBA; Virend K. Somers, MD, PhD; Pam R. Taub, MD, FACC, FASPC

Changing Behavior Using Digital Health for Long Term Weight Management

During this session, Dr. Hagger will cover:
  • How digital health apps and web interventions should use numerous methods and techniques to promote change in the adaptive weight-management behaviors (e.g., physical activity, healthy eating) in targeted populations to maintain a healthy weight
  • How these techniques and methods tap into psychological ‘constructs’ (e.g., attitudes, beliefs, self-efficacy, negative affect, implicit biases) and are likely to be reliably linked to health behavior adoption of key behaviors implicated in adaptive weight management
  • Potential uses of digital interventions, including setting effective goals, promoting successful experience with the behavior, managing negative thoughts, promoting self-confidence, prompting self-monitoring, identifying cues and prompts to the behavior, and developing effective action plans to use cues/prompts and deal with derailing contingencies.

The Role of CGM in the Management of Type 2 Diabetes:
Patient Selection & Important Pearls

During this session, Dr. Aleppo will cover:

  • The growing evidence about the utility of CGM in patients with type 2 diabetes (T2D)
  • How CGM benefits extend to patients with T2D on less intensive insulin therapy, as well as those not on insulin therapy
  • Review of key CGM metrics and their practical application to individualize therapy for patients with T2D

 

Statin Intolerance: How To Assess and Practical Pearls for Addressing It

During this session, Dr. Michos will cover:
  • Burden, symptoms, and definition of statin intolerance
  • Strategies to address statin intolerance, including how to identify a tolerable statin regimen, which may involve change in the type of statin, the dose, or the dosing regimen
  • How to employ a patient-centered approach to address statin intolerance

Hypertriglyceridemia: Trials, Tribulations, and Transition to Clinical Practice

During this session, Dr. Shapiro will cover:

  • The latest findings from clinical trials investigating triglyceride medications as a potential intervention to reduce atherosclerotic cardiovascular disease (ASCVD) risk.
  • The challenges and lessons learned from conducting clinical trials focused on hypertriglyceridemia, shedding light on the efficacy and safety profiles of these medications.
  • The pipeline of future triglyceride lowering drugs.
 

Early Treatment Intensification in Type 2 Diabetes

During this session, Dr. Frias will cover:

  • The importance of early treatment of patients with type 2 diabetes to address glucose control, obesity, as well as cardiorenal and hepatic risk.
  • Current and upcoming pharmacotherapeutics that, based on evidence, should be used early in the management of patients with type 2 diabetes to improve long-term outcomes.
  • A typical case of a patient with T2D who requires early, aggressive therapy for best short- and long-term outcomes.
 

Resistant Hypertension: Definitions, Current Treatment and Emerging Approaches

During this session, Dr. Cohen will cover:
  • Tips and pearls for the accurate diagnosis of resistant hypertension  (RH)
  • When to initiate a work up for secondary hypertension
  • Current treatment approaches for RH
  • New and emerging treatment approaches (drugs and devices) for RH
 

Sleep and Hypertension: A Two-Way Street

During this session, Dr. Somers will cover:

  • The physiology of normal sleep
  • The prohypertensive pathophysiology of disrupted sleep
  • How hypertension may be implicated in sleep disruption
   

Subscribe

Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.